ADC Therapeutics (ADCT) Short term Debt (2020 - 2026)

ADC Therapeutics' (ADCT) quarterly Short term Debt came in at $4.6 million in Q1 2026, up 54.5% quarter-over-quarter from $3.0 million in Q4 2025.

ADC Therapeutics (ADCT) Short term Debt (2020 - 2026) Analysis & Trends

ADC Therapeutics has disclosed Short term Debt across 3 years of filings, most recently posting $4.6 million for Q1 2026.

Short term Debt for Q1 2026 came in at $4.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (changed N/A YoY), and the FY2025 annual result was $3.0 million, changed N/A from the prior year.
Short term Debt came in at $4.6 million for Q1 2026 at ADC Therapeutics, up from $3.0 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $4.6 million in Q1 2026 to a low of $3.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	ADC Therapeutics	167.24 Mn	-63.76 Mn	7.33 Mn

Download Data